Pioneering Medical Innovations
Ocular reported Q2 2026 results, confirming the AXPAXLI wet AMD NDA submission remains on track for Q4 2026 following a positive Type C meeting with the FDA.
Ocular reported Q1 2026 results, with a cash balance of $666.7 million and expected runway into 2028, following the positive SOL-1 readout.
Ocular announced a June 17 Investor Day in New York featuring company leadership and prominent retinal disease experts.
SOL-1 met its superiority primary endpoint, the first successful demonstration of superiority in an FDA-aligned wet AMD trial comparing a novel investigative agent to an approved anti-VEGF treatment.
Ocular announced it would report topline SOL-1 Phase 3 data on February 17, 2026, with detailed data to follow at the 49th Macula Society Annual Meeting.
David W. Robinson, a commercial leader who helped architect the launch of EYLEA at Regeneron, was appointed Global Chief Commercial Officer.
Ocular reported Q3 2024 results, highlighting progress in the SOL-1 and SOL-R registrational trials of AXPAXLI in wet AMD and a cash balance of $427.2 million expected to fund operations into 2028.
151 subjects enrolled in various stages of loading and randomization in SOL-1 pivotal study of AXPAXLI in wet AMD as
Recent Leadership Appointments Put Ocular on Track to Become a Leader in Retinal Care Site Activation and Patient Enrollment for
46.2% of patients demonstrated a 1- or 2-step improvement in the Diabetic Retinopathy Severity Scale (DRSS) at 40 weeks in